Related Experiment Video
Updated: Aug 14, 2026
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
Treatment of short children born small for gestational age: US perspective, 2005
1University of Cincinnati School of Medicine and Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA. steven.chernausek@cchmc.org
Insights
Growth hormone (GH) therapy for short children born small for gestational age (SGA) has differing guidelines in the US and EU. These differences impact treatment initiation, dosage, and eligibility criteria for short stature.
Area of Science:
- Pediatrics
- Endocrinology
- Pharmacology
Background:
- Growth hormone (GH) administration is approved for treating short children born small for gestational age (SGA) in the US and EU.
- Regulatory bodies in both regions reviewed similar data for GH treatment in this population.
Purpose of the Study:
- To compare and contrast the specific indications, dosages, and treatment initiation criteria for GH therapy in short SGA children between the US and EU regulatory bodies.
- To highlight the differences in prescribed GH regimens and monitoring guidelines.
Main Methods:
- Comparative analysis of US and EU regulatory product labeling for GH treatment in short SGA children.
- Review of clinical datasets used by regulatory agencies for approval.
Main Results:
- US labeling offers greater flexibility in GH dosage and treatment initiation but provides less specific guidance.
- EU labeling is more prescriptive, with restrictions on GH dosage, patient height, and detailed monitoring protocols.
Conclusions:
- Despite similar underlying data, significant discrepancies exist in GH therapy guidelines for short SGA children between the US and EU.
- These differences necessitate careful consideration by practitioners regarding treatment protocols and patient selection based on regional approvals.
Abstract:
Growth hormone (GH) administration to ameliorate growth deficiency of short children born small for gestational age (SGA) is currently approved in the US and the EU. Even though regulatory bodies from each examined similar datasets concerning GH treatment of short SGA children, the specifics of indications for treatment and recommended regimens differed with respect to GH dosage, age at which therapy might be initiated, and the degree of short stature required. US product labeling allows more flexibility but provides less guidance for the practitioner. The EU tends to be more proscriptive, limiting use to shorter children, restricting the dosage, and providing specific guidelines in terms of monitoring during treatment.
